Merrion Pharm Plc (IRSH) - Novo Nordisk Trial Result RNS Number : 8550P Merrion Pharmaceuticals Public Ltd 31 October 2012 Novo Nordisk A/S Successfully Completes Single Dose Phase 1 Trial of Oral GLP-1 Analogue (NN9926) Using Merrion Pharmaceuticals GIPET Technology. Merrion Pharmaceuticals plc (ESM:MERR), today announces that its partner, Novo Nordisk, successfully completed a Phase I trial with an oral formulation of a Novo Nordisk proprietary GLP-1 analogue. Merrion's proprietary GIPET Technology was incorporated in the formulation in order to enhance the oral bioavailability of the drug. The aim of the trial was to investigate the safety, tolerance and pharmacokinetics, of the GLP-1 analogue NN9926. Under the terms of the license agreement signed in January 2009, Merrion will receive payments for products developed under the agreement. Payments are based on achievement of certain development, regulatory and sales milestones as well as royalties. Certain milestone payments have been received by Merrion as a result of this successful Phase 1 trial. Merrion's Chairman, Michael Donnelly said "We are very pleased with this outcome and the commitment of Novo Nordisk to the continuing development of Merrion's GIPET technology in this field". This information is provided by RNS The company news service from the London Stock Exchange END MSCBKKDDBBDDOKN -0- Oct/31/2012 09:00 GMT
Merrion Pharm Plc IRSH Novo Nordisk Trial Result
Press spacebar to pause and continue. Press esc to stop.